Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5304 |
Name | ovarian clear cell adenocarcinoma |
Definition | A ovarian adenocarcinoma that derives_from epithelial cells which have clear cytoplasm. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer ovary epithelial cancer malignant ovarian surface epithelial-stromal neoplasm ovarian carcinoma ovary adenocarcinoma ovarian clear cell adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA act mut | Dactolisib | ovarian clear cell adenocarcinoma | sensitive | detail... |
TP53 mutant | DS-7423 | ovarian clear cell adenocarcinoma | decreased response | detail... |
PIK3CA C420R | DS-7423 | ovarian clear cell adenocarcinoma | sensitive | detail... |
PIK3CA E545V | DS-7423 | ovarian clear cell adenocarcinoma | sensitive | detail... |
PIK3CA H1047R TP53 S90fs | DS-7423 | ovarian clear cell adenocarcinoma | decreased response | detail... |
TP53 S241F | DS-7423 | ovarian clear cell adenocarcinoma | decreased response | detail... |
TP53 R175H | DS-7423 | ovarian clear cell adenocarcinoma | decreased response | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01914510 | Phase II | ENMD-2076 | A Study of ENMD-2076 in Ovarian Clear Cell Cancers | Completed | CAN | 0 |
NCT02068794 | Phase Ib/II | MV-NIS | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02315430 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Active, not recruiting | USA | ITA | GBR | ESP | 2 |
NCT03602859 | Phase III | Dostarlimab-gxly + Niraparib Niraparib | A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | 2 |
NCT04065269 | Phase II | Ceralasertib + Olaparib Ceralasertib | ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) | Recruiting | GBR | CAN | 0 |
NCT04498117 | Phase III | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) | Active, not recruiting | USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG | 5 |